bioAffinity Technologies, Inc. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
bioAffinity Technologies reported Q2 2026 CyPath Lung test volume increased 216% year-over-year, with revenue of $1.51M (up 19% YoY). The company completed a June 2026 public offering generating $3.2M gross proceeds. However, cash declined from $6.4M (Dec 31, 2025) to $2.4M (June 30, 2026), and net loss was $3.4M in Q2 2026 versus $4.1M in Q2 2025.
Why this rating
Strong commercial traction (216% volume growth) and pipeline expansion are material for a $22.6M market-cap biotech. However, rapid cash burn ($4M in 6 months post-raise) and continued losses temper growth optimism. Nasdaq delisting risk disclosed.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.